Detection of circulating tumor cells during long-term follow-up of high-risk breast cancer patients indicates poor prognosis – results of the adjuvant SUCCESS A trial
E Trapp, B Rack, TW Friedl, L Häberle, H Tesch, R Lorenz, J Jückstock, M Tzschaschel, M Alunni-Fabbroni, A Schramm, J Koch, B Jäger, V Müller, S Mahner, T Fehm, A Schneeweiss, MW Beckmann, W Lichtenegger, C Scholz, W Janni · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Purpose: Recent data suggest that circulating tumor cells (CTCs) are of prognostic relevance in early and metastatic breast cancer (BC). However, there is a lack of information regarding the prognostic impact of detected CTCs during long-term follow-up. Methods: The multicenter, open label, Phase III trial SUCCESS A compared two adjuvant chemotherapy regimens followed by 2 versus 5 years of zoledronate in high-risk early BC patients. CTCs were assessed before and 2 years after chemotherapy using the FDA approved CellSearch System (Janssen Diagnostics, LLC). CTC-positivity was defined as ≥1 CTC in 7.5 ml whole bl…
